Please login to the form below

Immuno-oncology: The market opportunity for PD-1/PD-L1s


Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.

http://www.researchpartnership.com/news/2016/08/infographic-immunno-oncology/

23rd November 2016

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Pharma China Annual Forum 2017
We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.
Research Partnership
Healthcare Market Research in the Gulf: 3 lessons I’ve learned
A few key considerations for conducting healthcare market research in the Gulf
Research Partnership
Case study: Multiple Sclerosis new medical device research

Research Partnership
Patient Centricity: Turning Rhetoric into Reality
Live webinar: Thursday 30th March 10:00 EDT / 15:00 BST / 16:00 CEST
Research Partnership
Live from Singapore: Understanding patient willingness to pay in emerging markets
Live webinar: Thursday 23rd March 16:00 SGT / 16:00 CST / 17:00 JST
Research Partnership
Making sense of Nutraceuticals in China
Published in eyeforpharma February 2017 by Marc Yates
Research Partnership